Topical Drug Delivery Market

Topical Drug Delivery Market by Type (Semisolids (Creams, Ointments, Gels, Lotions, Liquids, Solids, Transdermal Products), Route (Dermal, Rectal, Vaginal), Patient Care Setting (Homecare, Hospital, Burn Center) COVID-19 Impact - Global Forecast to 2025

Report Code: PH 7545 Sep, 2020, by marketsandmarkets.com

[275 Pages Report] The topical drug delivery market is projected to reach USD 129.8 billion by 2025 from USD 95.2 billion in 2020, at a CAGR of 6.4% during the forecast period. The growth of this market is majorly driven by the high prevalence of skin and soft tissue infections, the increasing prevalence of eye diseases, and burns. However, the presence of alternative drug delivery modes such as oral and injectable routes is expected to restrain the growth of this market during the forecast period.

Topical Drug Delivery Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 Impact on Global Topical Drug Delivery Market

According to our findings, the topical drug delivery market is expected to grow at an approximate CAGR of 6-7% during the next two years. According to our analysis, the below factors are playing a key role in shaping the growth of the global market;

  • The number of COVID-19 cases has been increasing at an alarming rate in the US. The need for improved patient care and the adoption of drugs such as vitamin C, multivitamins, and antivirals, to improve immunity levels, have surged as a result.
  • Due to the rapid spread of COVID-19 and increasing fear, drugs are being stocked by various end users and patients. This is expected to boost the growth of the topical drug delivery market from 2020–2021. Various companies have witnessed an increase in revenue in Q1 2020 as compared to Q1 2019. For example, AbbVie reported an increase of 16.8% in its revenue during this period. Similarly, Amgen recorded a revenue of USD 6,161 million in Q1 2020, an 11% increase as compared to Q1 2019 (USD 5,286 million).
  • Raw materials required for manufacturing drugs (such as drug components, equipment used in manufacturing) are at the risk of a supply shortage due to the temporary lockdown of manufacturing sites in areas affected by COVID-19 or travel restrictions impacting shipments.
  • The normalization of the global economy is expected to proceed slowly, with a gradual increase in the manufacturing and transportation of raw materials and associated equipment; this will lead to market growth from Q1 2021.

Topical Drug Delivery Market Dynamics

Driver:  High prevalence of skin diseases

According to the Global Burden of Disease Project, skin diseases such as psoriasis, eczema, skin cancer, and vitiligo continue to be the fourth-leading cause of nonfatal disease burden worldwide and affect a large proportion of the global population. According to the WHO, between 2 and 3 million cases of non-melanoma skin cancer and 132,000 cases of melanoma skin cancer are diagnosed annually across the globe. Furthermore, the prevalence of psoriasis worldwide ranges between 0.09% and 11.43%, making it a serious global problem with at least 100 million individuals affected worldwide (Source: WHO 2016). As topical drug delivery is the first line of treatment for the majority of skin diseases, the demand for advanced topical products is expected to increase in the coming years.

Restraint: Preference for alternative modes of drug delivery

Several alternative drug delivery modes are available for patients and end users. The benefits of these alternatives over topical drug delivery form a key restraint to the growth of this market. Of these, the oral route is the most preferred as it is easy to use, convenient, cost-effective, safe, and acceptable. Furthermore, orally administered drugs can be conveniently stored and are portable, economical, noninvasive, and safe. No special training is required for the administration of these drugs as compared to topical formulations. Injectables also witness widespread use—for example, insulin injections for diabetics to self-administer.

Opportunity: Delivery of biologics through the transdermal route

The delivery of biologics through the transdermal route is one of the emerging trends in the topical drug delivery market. The transdermal delivery of large molecules as an alternative to intramuscular, subcutaneous, or intravenous routes of administration is expected to provide significant patient benefits, such as painless drug delivery and cost-effective treatment.

Challenge:  Technical barriers related to skin irritation and permeability

The potential for local adverse reactions and skin irritation is a significant challenge for topical drug delivery formulation and transdermal systems. However, the emergence of novel techniques for skin permeation and the development of methods to reduce skin irritation would help widen the topical drug delivery formulations and transdermal systems market for hydrophilic compounds, macromolecules, and conventional drugs for new therapeutic indications.

The semi-solid formulations segment accounts for the largest share of the market, by product, in 2019

Based on product, the topical drug delivery market is segmented into semi-solid formulations, liquid formulations, solid formulations, and transdermal products. The semi-solid formulations segment accounted for the larger market share in 2019. The easy application of semi-solid formulations, and their ability to deliver a wide variety of drug molecules is resulting in a stable demand for this segment among end users.

The dermal drug delivery segment is expected to grow at the highest CAGR during the forecast period

Based on route of administration, the topical drug delivery market is segmented into dermal drug delivery, ophthalmic drug delivery, rectal, vaginal drug delivery, and nasal drug delivery. The dermal drug delivery segment is expected to witness the highest growth during the forecast period. This is mainly due to the advantages of dermal drug delivery over other topical drug delivery methods, such as convenience and greater patient compliance. Besides, dermal products have fewer regulatory requirements than ophthalmic products, where sterility testing is mandatory.

The home care settings segment is expected to account for the largest share of the topical drug delivery market in 2019

The home care settings segment accounted for the largest share of the market in 2019. This is attributed to the factors such as the convenience and affordability of topical drugs for home administration. Also, for patients requiring long-term therapy, inpatient care is not only extremely expensive but also prevents patients from resuming a normal lifestyle and work activities. In this regard, technological advancements have helped patients undergo therapies effectively and safely at home.

Asia Pacific is expected to grow at the highest CAGR in the topical drug delivery market during the forecast period

The topical drug delivery market in the Asia Pacific is estimated to grow at the highest CAGR during the forecast period. This is due to high incidence of skin diseases (such as skin cancer), increasing use of contraceptives, and the growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, all of which are driving adoption of topical drug delivery in the Asia Pacific.

Topical Drug Delivery Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players

The prominent players in this market are Johnson & Johnson (US), Nestle SA (Switzerland), Novartis AG (Switzerland), GlaxoSmithKline (UK), Bausch Health Companies (Canada), Merck & Co (US), and Bayer AG (Germany).

Report Scope

Report Metric

Details

Market size available for years

2018–2025

Base year considered

2019

Forecast period

2020–2025

Forecast units

Value (USD)

Segments covered

Product, Route of Administration, and Facility of Use

Geographies covered

North America, Europe, Asia Pacific, Rest of the World

Companies covered

Johnson & Johnson (US), Nestlι SA (Switzerland), Novartis AG (Switzerland), GlaxoSmithKline (UK), Bausch Health Companies (Canada), Merck & Co (US), Bayer AG (Germany), Hisamitsu Pharmaceutical (Japan), Glenmark Pharmaceuticals (India), Cipla Ltd (India), Crescita Therapeutics Inc. (Canada), Mylan (US), Encore Dermatology, Inc. (US), LEO Pharma (Denmark), Almirall, S.A (Spain), Aclaris Therapeutics, Inc. (US), Taro Pharmaceutical Industries Ltd. (US), Teligent Pharma (US), Perrigo Pharma (US), Allergan (Ireland), Biofrontera, Inc. (US), Crown Laboratories Inc. (US), Akorn Inc. (US), Ingenus Pharmaceuticals (US), and Sun Pharmaceuticals (India)

The study categorizes the Topical Drug Delivery Market based on product, route of administration, facility of use, and regional and global level.

Global Topical Drug Delivery Market, by Product

  • Semi-Solid Formulations
    • Creams
    • Ointments
    • Lotions
    • Gels
    • Pastes
  • Liquid Formulations
    • Solutions
    • Suspensions
  • Solid Formulations
    • Powders
    • Suppositories
  • Transdermal Products
    • Transdermal Patches
    • Transdermal Semi-solids

Global Topical Drug Delivery Market, by Route of Administration

  • Dermal Drug Delivery
  • Ophthalmic Drug Delivery
  • Rectal Drug Delivery
  • Vaginal Drug Delivery
  • Nasal Drug Delivery

Global Topical Drug Delivery Market, by Facility of Use

  • Home Care Settings
  • Hospitals & Clinics
  • Burn Centers
  • Other Facilities

Global Topical Drug Delivery Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of APAC
  • Rest of the World

Recent Developments

  • In 2019, Mylan launched its DICLOFENAC SODIUM Gel.
  • In 2019, Nestlι Skin Health opened a new office in Malaysia to accelerate growth in the Southeast Asian market.
  • In 2019, Crescita Therapeutics signed an out-licensing agreement with Cantabria labs for the sales and distribution of its topical Pliaglis formulation in Italy, Portugal, France, and Spain.
  • In 2018, Bausch Healthcare expanded its manufacturing facility in Rochester (Ireland) in order to support and fulfill the demand of its topical eye health products.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 37)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS
           1.2.2 MARKETS COVERED
                 FIGURE 1 TOPICAL DRUG DELIVERY MARKET SEGMENTATION
           1.2.3 YEARS CONSIDERED FOR THE STUDY
    1.3 CURRENCY
    1.4 LIMITATIONS
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 41)
    2.1 RESEARCH DATA
        FIGURE 2 TOPICAL DRUG DELIVERY MARKET: RESEARCH METHODOLOGY
        FIGURE 3 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
    2.2 MARKET SIZING & VALIDATION APPROACH
        FIGURE 5 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS
        FIGURE 6 TOP-DOWN APPROACH
    2.3 MARKET DATA VALIDATION AND TRIANGULATION
        FIGURE 7 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ANALYSIS
    2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 51)
  FIGURE 8 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020 VS 2025 (USD MILLION)
  FIGURE 9 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020 VS 2025 (USD MILLION)
  FIGURE 10 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020 VS 2025 (USD MILLION)
  FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE TOPICAL DRUG DELIVERY MARKET

4 PREMIUM INSIGHTS (Page No. - 54)
    4.1 TOPICAL DRUG DELIVERY MARKET OVERVIEW
        FIGURE 12 HIGH PREVALENCE OF SKIN DISEASES AND HIGH INCIDENCE OF BURN INJURIES TO DRIVE THE GROWTH OF THE TOPICAL DRUG DELIVERY MARKET
    4.2 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT AND COUNTRY, 2019
        FIGURE 13 SEMI-SOLID FORMULATIONS TO DOMINATE THE ASIA PACIFIC MARKET DURING THE FORECAST PERIOD
    4.3 TOPICAL DRUG DELIVERY MARKET, BY REGION (2018-2025)
        FIGURE 14 NORTH AMERICA WILL CONTINUE TO DOMINATE THE TOPICAL DRUG DELIVERY MARKET IN 2025
    4.4 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
        FIGURE 15 CHINA TO SHOW THE HIGHEST REVENUE GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 58)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
        FIGURE 16 TOPICAL DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 High prevalence of skin diseases
                    5.2.1.2 Rising prevalence of eye diseases
                    5.2.1.3 High incidence of burn injuries
                    5.2.1.4 Growing prevalence of diabetes
           5.2.2 RESTRAINTS
                    5.2.2.1 Preference for alternative modes of drug delivery
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Delivery of biologics through the transdermal route
                    5.2.3.2 Self-administration and home care
           5.2.4 CHALLENGES
                    5.2.4.1 Technical barriers related to skin irritation and permeability
                    5.2.4.2 Drug failures and product recalls
    5.3 COVID-19 IMPACT ON THE TOPICAL DRUG DELIVERY MARKET
        FIGURE 17 IMPACT OF COVID-19 ON THE TOPICAL DRUG DELIVERY MARKET

6 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT (Page No. - 64)
    6.1 INTRODUCTION
    6.2 COVID-19 IMPACT, BY PRODUCT
        FIGURE 18 SEMI-SOLID FORMULATIONS SEGMENT TO COMMAND THE LARGEST SHARE OF THE MARKET IN 2019
        TABLE 1 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017–2019 (USD MILLION)
        TABLE 2 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
    6.3 SEMI-SOLID FORMULATIONS
        TABLE 3 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
        TABLE 4 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 5 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS,  BY COUNTRY, 2017–2019 (USD MILLION)
        TABLE 6 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2020–2025 (USD MILLION)
           6.3.1 CREAMS
                    6.3.1.1 Ease of spreadability and washability to drive this market segment
                            TABLE 7 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY COUNTRY, 2017–2019 (USD MILLION)
                            TABLE 8 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY COUNTRY, 2020–2025 (USD MILLION)
           6.3.2 OINTMENTS
                    6.3.2.1 Ointments are widely used in analgesic indications
                            TABLE 9 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY COUNTRY, 2017–2019 (USD MILLION)
                            TABLE 10 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY COUNTRY, 2020–2025 (USD MILLION)
           6.3.3 LOTIONS
                    6.3.3.1 Easy administration of lotions to drive their demand among end users
                            TABLE 11 TOPICAL DRUG DELIVERY MARKET FOR LOTIONS, BY COUNTRY, 2017–2019 (USD MILLION)
                            TABLE 12 TOPICAL DRUG DELIVERY MARKET FOR LOTIONS, BY COUNTRY, 2020–2025 (USD MILLION)
           6.3.4 GELS
                    6.3.4.1 Faster drug release and greater patient acceptability to drive the market for topical gels
                            TABLE 13 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY COUNTRY, 2017–2019 (USD MILLION)
                            TABLE 14 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY COUNTRY, 2020–2025 (USD MILLION)
           6.3.5 PASTES
                    6.3.5.1 Topical pastes are widely used for the treatment and prevention of skin irritation
                            TABLE 15 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY COUNTRY, 2017–2019 (USD MILLION)
                            TABLE 16 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY COUNTRY, 2020–2025 (USD MILLION)
    6.4 LIQUID FORMULATIONS
        TABLE 17 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
        TABLE 18 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 19 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2017–2019 (USD MILLION)
        TABLE 20 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2020–2025 (USD MILLION)
           6.4.1 SUSPENSIONS
                    6.4.1.1 Higher rate of bioavailability and controlled onset of action to support the growth of the topical suspensions market
                            TABLE 21 TOPICAL DRUG DELIVERY MARKET FOR SUSPENSIONS, BY COUNTRY, 2017–2019 (USD MILLION)
                            TABLE 22 TOPICAL DRUG DELIVERY MARKET FOR SUSPENSIONS, BY COUNTRY, 2020–2025 (USD MILLION)
           6.4.2 SOLUTIONS
                    6.4.2.1 Topical solutions comprise soluble chemicals that are dissolved in various solvents
                            TABLE 23 TOPICAL DRUG DELIVERY MARKET FOR SOLUTIONS, BY COUNTRY, 2017–2019 (USD MILLION)
                            TABLE 24 TOPICAL DRUG DELIVERY MARKET FOR SOLUTIONS, BY COUNTRY, 2020–2025 (USD MILLION)
    6.5 SOLID FORMULATIONS
        TABLE 25 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
        TABLE 26 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 27 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2017–2019 (USD MILLION)
        TABLE 28 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2020–2025 (USD MILLION)
           6.5.1 POWDERS
                    6.5.1.1 Powders have a very fine particle size that covers a large surface area per unit weight
                            TABLE 29 TOPICAL DRUG DELIVERY MARKET FOR POWDERS, BY COUNTRY,  2017–2019 (USD MILLION)
                            TABLE 30 TOPICAL DRUG DELIVERY MARKET FOR POWDERS, BY COUNTRY, 2020–2025 (USD MILLION)
           6.5.2 SUPPOSITORIES
                    6.5.2.1 Suppositories require a suitable base that ensures the compatibility and stability of the drug
                            TABLE 31 TOPICAL DRUG DELIVERY MARKET FOR SUPPOSITORIES, BY COUNTRY, 2017–2019 (USD MILLION)
                            TABLE 32 TOPICAL DRUG DELIVERY MARKET FOR SUPPOSITORIES, BY COUNTRY, 2020–2025 (USD MILLION)
    6.6 TRANSDERMAL PRODUCTS
        TABLE 33 COMPARISON BETWEEN TRANSDERMAL PATCHES AND TRANSDERMAL SEMI-SOLID FORMULATIONS
        TABLE 34 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION)
        TABLE 35 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,  BY TYPE, 2020–2025 (USD MILLION)
        TABLE 36 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2017–2019 (USD MILLION)
        TABLE 37 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2020–2025 (USD MILLION)
           6.6.1 TRANSDERMAL PATCHES
                    6.6.1.1 Transdermal patches accounted for the largest share of the transdermal drug delivery market in 2019
                            TABLE 38 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY COUNTRY, 2017–2019 (USD MILLION)
                            TABLE 39 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY COUNTRY, 2020–2025 (USD MILLION)
           6.6.2 TRANSDERMAL SEMI-SOLIDS
                    6.6.2.1 Transdermal semi-solids segment to witness negative growth during the forecast period
                            TABLE 40 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL SEMI-SOLIDS,  BY COUNTRY, 2017–2019 (USD MILLION)
                            TABLE 41 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL SEMI-SOLIDS,  BY COUNTRY, 2020–2025 (USD MILLION)

7 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 96)
    7.1 INTRODUCTION
    7.2 COVID-19 IMPACT, BY ROUTE OF ADMINISTRATION
        FIGURE 19 DERMAL DRUG DELIVERY TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
        TABLE 42 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
        TABLE 43 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION)
    7.3 DERMAL DRUG DELIVERY
           7.3.1 DERMAL DRUG DELIVERY IS THE LARGEST SEGMENT IN THIS MARKET
                 TABLE 44 DERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2017–2019 (USD MILLION)
                 TABLE 45 DERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2025 (USD MILLION)
    7.4 OPHTHALMIC DRUG DELIVERY
           7.4.1 INCREASING USE OF MOBILE DEVICES IS LIKELY TO IMPACT VISION, WHICH IS A KEY FACTOR SUPPORTING MARKET GROWTH
                 TABLE 46 OPHTHALMIC DRUG DELIVERY MARKET, BY COUNTRY, 2017–2019 (USD MILLION)
                 TABLE 47 OPHTHALMIC DRUG DELIVERY MARKET, BY COUNTRY, 2020–2025 (USD MILLION)
    7.5 RECTAL DRUG DELIVERY
           7.5.1 POOR ABSORPTION OF DRUGS THROUGH THE RECTAL ROUTE—A KEY DISADVANTAGE ASSOCIATED WITH THIS MARKET SEGMENT
                 TABLE 48 RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2017–2019 (USD MILLION)
                 TABLE 49 RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2025 (USD MILLION)
    7.6 VAGINAL DRUG DELIVERY
           7.6.1 SCOPE OF SELF-ADMINISTRATION AND EASE OF MANUFACTURING TO BOOST THE GROWTH OF THE VAGINAL DRUG DELIVERY MARKET SEGMENT
                 TABLE 50 VAGINAL DRUG DELIVERY MARKET, BY COUNTRY, 2017–2019 (USD MILLION)
                 TABLE 51 VAGINAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2025 (USD MILLION)
    7.7 NASAL DRUG DELIVERY
           7.7.1 HIGH EFFICACY OF NASALLY ADMINISTERED DRUGS AND GROWING PREFERENCE FOR SELF-ADMINISTRATION TO DRIVE MARKET GROWTH
                 TABLE 52 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2017–2019 (USD MILLION)
                 TABLE 53 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2025 (USD MILLION)

8 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE (Page No. - 106)
    8.1 INTRODUCTION
        FIGURE 20 HOME CARE SETTINGS SEGMENT TO COMMAND THE LARGEST SHARE OF THE MARKET IN 2019
        TABLE 54 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017–2019 (USD MILLION)
        TABLE 55 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2025 (USD MILLION)
    8.2 HOME CARE SETTINGS
           8.2.1 HOME CARE SETTINGS ACCOUNTED FOR THE LARGEST SHARE IN 2019
                 TABLE 56 TOPICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2017–2019 (USD MILLION)
                 TABLE 57 TOPICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2020–2025 (USD MILLION)
    8.3 HOSPITALS AND CLINICS
           8.3.1 RISING INCIDENCE OF SURGICAL-SITE INFECTIONS TO DRIVE MARKET GROWTH
                 TABLE 58 TOPICAL DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2017–2019 (USD MILLION)
                 TABLE 59 TOPICAL DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2025 (USD MILLION)
    8.4 BURN CENTERS
           8.4.1 HIGH INCIDENCE OF BURN INJURIES ACROSS THE GLOBE TO SUPPORT THE MARKET GROWTH
                 TABLE 60 TOPICAL DRUG DELIVERY MARKET FOR BURN CENTERS, BY COUNTRY, 2017–2019 (USD MILLION)
                 TABLE 61 TOPICAL DRUG DELIVERY MARKET FOR BURN CENTERS, BY COUNTRY, 2020–2025 (USD MILLION)
    8.5 OTHER FACILITIES
        TABLE 62 TOPICAL DRUG DELIVERY MARKET FOR OTHER FACILITIES, BY COUNTRY, 2017–2019 (USD MILLION)
        TABLE 63 TOPICAL DRUG DELIVERY MARKET FOR OTHER FACILITIES, BY COUNTRY, 2020–2025 (USD MILLION)

9 TOPICAL DRUG DELIVERY MARKET, BY REGION (Page No. - 115)
    9.1 INTRODUCTION
    9.2 COVID-19 IMPACT, BY REGION
        FIGURE 21 CHINA TO WITNESS THE HIGHEST GROWTH IN THE TOPICAL DRUG DELIVERY MARKET
        TABLE 64 TOPICAL DRUG DELIVERY MARKET, BY REGION, 2017–2019 (USD MILLION)
        TABLE 65 TOPICAL DRUG DELIVERY MARKET, BY REGION, 2020–2025 (USD MILLION)
    9.3 NORTH AMERICA
        FIGURE 22 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
        TABLE 66 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2017–2019 (USD MILLION)
        TABLE 67 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2025 (USD MILLION)
        TABLE 68 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017–2019 (USD MILLION)
        TABLE 69 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
        TABLE 70 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
        TABLE 71 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 72 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
        TABLE 73 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 74 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
        TABLE 75 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 76 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION)
        TABLE 77 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 78 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
        TABLE 79 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION)
        TABLE 80 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017–2019 (USD MILLION)
        TABLE 81 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2025 (USD MILLION)
           9.3.1 US
                    9.3.1.1 Rising prevalence of skin diseases and the approval and launch of innovative topical formulations—key factors driving market growth
                            TABLE 82 PRODUCT APPROVALS & LAUNCHES IN THE US MARKET (2017–2019)
                            TABLE 83 US: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017–2019 (USD MILLION)
                            TABLE 84 US: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
                            TABLE 85 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 86 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 87 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 88 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 89 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 90 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 91 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 92 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 93 US: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                            TABLE 94 US: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION)
                            TABLE 95 US: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017–2019 (USD MILLION)
                            TABLE 96 US: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2025 (USD MILLION)
           9.3.2 CANADA
                    9.3.2.1 Rising prevalence of skin diseases and funding for the development of topical drugs to drive market growth
                            TABLE 97 CANADA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017–2019 (USD MILLION)
                            TABLE 98 CANADA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
                            TABLE 99 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 100 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 101 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 102 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 103 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,  BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 104 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 105 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 106 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 107 CANADA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                            TABLE 108 CANADA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION)
                            TABLE 109 CANADA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017–2019 (USD MILLION)
                            TABLE 110 CANADA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2025 (USD MILLION)
    9.4 EUROPE
        TABLE 111 RECENT DEVELOPMENTS IN THE EUROPEAN TOPICAL DRUG DELIVERY MARKET, 2015–2018
        FIGURE 23 EUROPE: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
        TABLE 112 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2017–2019 (USD MILLION)
        TABLE 113 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2025 (USD MILLION)
        TABLE 114 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017–2019 (USD MILLION)
        TABLE 115 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
        TABLE 116 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
        TABLE 117 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 118 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
        TABLE 119 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 120 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
        TABLE 121 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 122 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION)
        TABLE 123 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 124 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
        TABLE 125 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION)
        TABLE 126 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017–2019 (USD MILLION)
        TABLE 127 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2025 (USD MILLION)
           9.4.1 GERMANY
                    9.4.1.1 Growing focus of pharmaceutical companies on the development of topical products to drive market growth
                            TABLE 128 DEVELOPMENTS IN THE FIELD OF TOPICAL DRUG DELIVERY IN GERMANY, 2017–2019
                            TABLE 129 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017–2019 (USD MILLION)
                            TABLE 130 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
                            TABLE 131 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 132 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 133 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 134 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 135 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 136 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 137 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 138 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 139 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                            TABLE 140 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION)
                            TABLE 141 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017–2019 (USD MILLION)
                            TABLE 142 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,  2020–2025 (USD MILLION)
           9.4.2 UK
                    9.4.2.1 Rising prevalence of skin diseases & chronic conditions to drive market growth
                            TABLE 143 DEVELOPMENTS IN THE TOPICAL DRUG DELIVERY MARKET IN THE UK, 2016–2019
                            TABLE 144 UK: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017–2019 (USD MILLION)
                            TABLE 145 UK: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
                            TABLE 146 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 147 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 148 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 149 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 150 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 151 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 152 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 153 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 154 UK: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                            TABLE 155 UK: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION)
                            TABLE 156 UK: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017–2019 (USD MILLION)
                            TABLE 157 UK: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2025 (USD MILLION)
           9.4.3 FRANCE
                    9.4.3.1 Rising prevalence of skin diseases and development of topical drugs by local players to support market growth
                            TABLE 158 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017–2019 (USD MILLION)
                            TABLE 159 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
                            TABLE 160 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 161 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 162 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 163 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 164 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 165 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,  BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 166 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 167 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 168 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                            TABLE 169 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION)
                            TABLE 170 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017–2019 (USD MILLION)
                            TABLE 171 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2025 (USD MILLION)
           9.4.4 REST OF EUROPE
                 TABLE 172 ROE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017–2019 (USD MILLION)
                 TABLE 173 ROE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
                 TABLE 174 ROE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                 TABLE 175 ROE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                 TABLE 176 ROE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                 TABLE 177 ROE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                 TABLE 178 ROE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,  BY TYPE, 2017–2019 (USD MILLION)
                 TABLE 179 ROE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                 TABLE 180 ROE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION)
                 TABLE 181 ROE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION)
                 TABLE 182 ROE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                 TABLE 183 ROE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION)
                 TABLE 184 ROE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017–2019 (USD MILLION)
                 TABLE 185 ROE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2025 (USD MILLION)
    9.5 ASIA PACIFIC
        TABLE 186 DEVELOPMENTS IN THE TOPICAL DRUG DELIVERY MARKET IN THE ASIA PACIFIC, 2016–2019
        FIGURE 24 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
        TABLE 187 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2017–2019 (USD MILLION)
        TABLE 188 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2020–2025 (USD MILLION)
        TABLE 189 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017–2019 (USD MILLION)
        TABLE 190 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
        TABLE 191 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
        TABLE 192 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 193 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
        TABLE 194 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 195 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
        TABLE 196 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 197 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION)
        TABLE 198 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 199 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
        TABLE 200 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION)
        TABLE 201 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017–2019 (USD MILLION)
        TABLE 202 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2025 (USD MILLION)
           9.5.1 JAPAN
                    9.5.1.1 Increasing number of product approvals and growing focus of local players on the R&D of topical formulations to support market growth
                            TABLE 203 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017–2019 (USD MILLION)
                            TABLE 204 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
                            TABLE 205 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 206 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 207 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 208 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 209 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 210 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 211 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 212 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 213 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                            TABLE 214 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION)
                            TABLE 215 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017–2019 (USD MILLION)
                            TABLE 216 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2025 (USD MILLION)
           9.5.2 CHINA
                    9.5.2.1 Growing focus of major players in China on the development of topical drugs to drive market growth
                            TABLE 217 CHINA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017–2019 (USD MILLION)
                            TABLE 218 CHINA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
                            TABLE 219 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 220 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 221 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 222 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 223 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 224 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 225 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 226 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 227 CHINA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                            TABLE 228 CHINA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION)
                            TABLE 229 CHINA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017–2019 (USD MILLION)
                            TABLE 230 CHINA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2025 (USD MILLION)
           9.5.3 INDIA
                    9.5.3.1 Rising awareness among healthcare providers & patients and increasing focus on noninvasive methods of drug delivery to drive market growth
                            TABLE 231 INDIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017–2019 (USD MILLION)
                            TABLE 232 INDIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
                            TABLE 233 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 234 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 235 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 236 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 237 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 238 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 239 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION)
                            TABLE 240 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION)
                            TABLE 241 INDIA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                            TABLE 242 INDIA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION)
                            TABLE 243 INDIA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017–2019 (USD MILLION)
                            TABLE 244 INDIA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2025 (USD MILLION)
           9.5.4 REST OF ASIA PACIFIC
                 TABLE 245 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2017–2019 (USD MILLION)
                 TABLE 246 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
                 TABLE 247 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                 TABLE 248 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                 TABLE 249 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                 TABLE 250 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                 TABLE 251 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
                 TABLE 252 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
                 TABLE 253 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2017–2019 (USD MILLION)
                 TABLE 254 ROAPAC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2020–2025 (USD MILLION)
                 TABLE 255 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                 TABLE 256 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION)
                 TABLE 257 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017–2019 (USD MILLION)
                 TABLE 258 ROAPAC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2025 (USD MILLION)
    9.6 REST OF THE WORLD
        FIGURE 25 REST OF THE WORLD: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
        TABLE 259 ROW: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT,  2017–2019 (USD MILLION)
        TABLE 260 ROW: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2020–2025 (USD MILLION)
        TABLE 261 ROW: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
        TABLE 262 ROW: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 263 ROW: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2017–2019 (USD MILLION)
        TABLE 264 ROW: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS,  BY TYPE, 2020–2025 (USD MILLION)
        TABLE 265 ROW: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS,  BY TYPE, 2017–2019 (USD MILLION)
        TABLE 266 ROW: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 267 ROW: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,  BY TYPE, 2017–2019 (USD MILLION)
        TABLE 268 ROW: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS,  BY TYPE, 2020–2025 (USD MILLION)
        TABLE 269 ROW: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
        TABLE 270 ROW: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2020–2025 (USD MILLION)
        TABLE 271 ROW: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2017–2019 (USD MILLION)
        TABLE 272 ROW: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2020–2025 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 217)
     10.1 OVERVIEW
     10.2 MARKET SHARE ANALYSIS
          FIGURE 26 MARKET SHARE ANALYSIS BY KEY PLAYERS (2019)
     10.3 COMPETITIVE SCENARIO
             10.3.1 PRODUCT LAUNCHES
                                     TABLE 273 PRODUCT LAUNCHES
             10.3.2 EXPANSIONS
                    TABLE 274 EXPANSIONS
             10.3.3 AGREEMENTS AND COLLABORATIONS
                    TABLE 275 AGREEMENTS AND COLLABORATIONS
             10.3.4 ACQUISITIONS
                    TABLE 276 ACQUISITIONS
     10.4 COMPETITIVE LEADERSHIP MAPPING (OVERALL MARKET) (2019)
             10.4.1 STAR PLAYERS
             10.4.2 EMERGING LEADERS
             10.4.3 PERVASIVES
             10.4.4 EMERGING COMPANIES
                    FIGURE 27 TOPICAL DRUG DELIVERY MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2019

11 COMPANY PROFILES (Page No. - 222)
(Business Overview, Products Offered, Recent Developments, and MnM View)*
     11.1 BAUSCH HEALTH COMPANIES
          FIGURE 28 BAUSCH HEALTH COMPANIES: COMPANY SNAPSHOT (2019)
     11.2 HISAMITSU PHARMACEUTICAL
          FIGURE 29 HISAMITSU PHARMACEUTICAL: COMPANY SNAPSHOT (2019)
     11.3 NESTLΙ SA
          FIGURE 30 NESTLΙ SA: COMPANY SNAPSHOT (2019)
     11.4 GLENMARK PHARMACEUTICALS
          FIGURE 31 GLENMARK PHARMACEUTICALS: COMPANY SNAPSHOT (2019)
     11.5 CIPLA
          FIGURE 32 CIPLA: COMPANY SNAPSHOT (2020)
     11.6 CRESCITA THERAPEUTICS INC.
          FIGURE 33 CRESCITA THERAPEUTICS: COMPANY SNAPSHOT (2019)
     11.7 MYLAN N.V.
          FIGURE 34 MYLAN: COMPANY SNAPSHOT (2019)
     11.8 GLAXOSMITHKLINE
          FIGURE 35 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2019)
     11.9 JANSSEN GLOBAL SERVICES (A SUBSIDIARY OF JOHNSON & JOHNSON)
          FIGURE 36 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2019)
     11.10 3M
           FIGURE 37 3M: COMPANY SNAPSHOT (2019)
     11.11 MERCK & CO.
           FIGURE 38 MERCK & CO.: COMPANY SNAPSHOT (2019)
     11.12 BAYER AG
           FIGURE 39 BAYER AG: COMPANY SNAPSHOT (2019)
     11.13 NOVARTIS AG
           FIGURE 40 NOVARTIS AG: COMPANY SNAPSHOT (2019)
     11.14 BOEHRINGER INGELHEIM
           FIGURE 41 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2019)
     11.15 PFIZER, INC.
           FIGURE 42 PFIZER, INC.: COMPANY SNAPSHOT (2019)
     11.16 OTHER MAJOR COMPANIES
             11.16.1 TEVA PHARMACEUTICALS
             11.16.2 BRISTOL-MYERS SQUIBB
             11.16.3 LEAD CHEMICALS CO., INC.
             11.16.4 LAVIPHARM
             11.16.5 PURDUE PHARMA L.P.

*Details on Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.

12 APPENDIX (Page No. - 268)
     12.1 DISCUSSION GUIDE
     12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.3 RELATED REPORTS
     12.4 AUTHOR DETAILS

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the use of comprehensive secondary sources; directories and databases such as D&B, Bloomberg Business, and Factiva; and white papers, annual reports, and company house documents. Secondary research was used to identify and collect information for this extensive, technical, market-oriented, and commercial study of the global topical drug delivery market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, technology perspectives, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, manufacturing managers, and related key executives from various key companies and organizations operating in the global topical drug delivery market. The primary sources from the demand side include purchase and sales managers, research organizations, and pharmaceutical and biotechnology companies.

Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and market dynamics.

A breakdown of the primary respondents is provided below:

Topical Drug Delivery Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by product, route of administration, facility of use, and region).

Data Triangulation

After arriving at the market size, the total topical drug delivery market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, data triangulation, and market breakdown procedures were employed, wherever applicable.

Objectives of the Study

  • To define, describe, and forecast the topical drug delivery market by product, route of administration, facility of use, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets1 for individual growth trends, prospects, and contributions to the overall topical drug delivery market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To strategically analyze the market structure and profile the key players of the topical drug delivery market and comprehensively analyze their core competencies2
  • To forecast the size of the market segments in four main regions, namely, North America, Europe, Asia Pacific (APAC), and the Rest of the World (RoW)3
  • To track and analyze competitive developments such as product launches, expansions, acquisitions, partnerships, collaborations, and agreements
  • To benchmark players within the topical drug delivery market using the "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)

Geographic Analysis

  • A further breakdown of the ROW topical drug delivery market into Brazil, Mexico, and other countries
COVID-19

Get in-depth analysis of the COVID-19 impact on the Topical Drug Delivery Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Topical Drug Delivery Market

Request For Special Pricing
Report Code
PH 7545
Published ON
Sep, 2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Topical Drug Delivery Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2020 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home